28 Feb 2019 07:00
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN
REDX PHARMA PLC
("Redx" or "the Company")
Issue of Warrants and Change to Lease Agreement
Alderley Park, 28 February 2019 Redx (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis, announces that, as previously noted in its 2018 Annual Report, it has successfully completed an agreement with Alderley Park Limited to significantly reduce its accommodation footprint in the Company's Headquarters at Alderley Park, Cheshire.
As part of the agreement, on 27 February 2019, a Warrant to acquire 750,000 ordinary shares of 1p each in the share capital of the Company was issued to Alderley Park Limited as follows:
The subscription price payable per warrant share on exercise of the warrant is:
Price | No. of Shares | Date of Vesting |
13.75p | 125,000 | 27 February 2019 |
20p | 125,000 | 27 February 2019 |
27p | 125,000 | 27 February 2020 |
35p | 125,000 | 27 February 2020 |
42.5p | 125,000 | 27 February 2021 |
50p | 125,000 | 27 February 2021 |
The Warrant will not become exercisable until the second anniversary of issue.
For further information, please contact:
Redx Pharma Plc | T: +44 1625 469 920 |
Lisa Anson, Chief Executive Officer |
|
|
|
Cantor Fitzgerald Europe (Nominated Advisor & Joint Broker) | T: +44 20 7894 7000 |
Phil Davies |
|
|
|
|
|
WG Partners LLP (Joint Broker) | T: +44 20 3705 9330 |
Claes Spång/ Chris Lee/ David Wilson |
|
|
|
|
|
FTI Consulting | T: +44 20 3727 1000 |
Simon Conway/Stephanie Cuthbert |
|
About Redx Pharma Plc
Redx is a UK based biotechnology company whose shares are traded on AIM (AIM:REDX). Redx's vision is to become a leading biotech focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases.
If you would like to sign up to regular alerts from Redx Pharma, please follow this link https://www.redxpharma.com/investors/email-alerts/